TRANSPLANTATION AND ADOPTIVE CELLULAR THERAPY OF CANCER - THE ROLE OF T-CELL GROWTH-FACTORS

被引:3
作者
LOTZE, MT
机构
[1] Department of Surgery, University of Pittsburgh Medical Center, the Pittsburgh Cancer Institute, Pittsburgh
关键词
IMMUNOTHERAPY; LYMPHOKINE-ACTIVATED KILLER CELLS; TUMOR INFILTRATING LYMPHOCYTES; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-7; INTERLEUKIN-10; INTERLEUKIN-12; ADOPTIVE TRANSFER;
D O I
10.1177/096368979300200106
中图分类号
Q813 [细胞工程];
学科分类号
摘要
The ability to transfer cultured lymphocytes required the availability and the understanding of the use of the T-cell growth factors IL-2, IL-4, IL-7, and IL-12. Application of these cytokines in vitro and in vivo has allowed the modern development of adoptive transfer of tumor reactive lymphocytes to the modern immunotherapy of patients with cancer. In a randomized prospective study of IL-2 administration compared with IL-2 and lymphokine-activated killer (LAK) cells, no increase in response rate was observed. In a total of 90 patients randomized to receive LAK and IL-2 and 91 patients randomized to receive IL-2 alone, there were a total of 24 responses in patients receiving cells and IL-2 and 16 responses in those receiving IL-2 alone (no significant difference). There was some suggestion that complete responses were observed more often in melanoma patients treated with LAK and IL-2. The most interesting aspect of this study is the prolonged duration of responses, lasting for many months or years. Unfortunately, given the large numbers of variables that were examined, it became very difficult to demonstrate a clear-cut association between clinical outcome (response) and any variable that was routinely measured. Significant antitumor responses have been observed greater than expected with IL-2 alone, with the administration of tumor-infiltrating lymphocytes to patients with melanoma. We currently use hollow fiber devices (Cellco, Germantown, MD) to expand cells up through the many doublings required to generate approximately 1-2 x 10(11) cells over a period of 6 wk in culture. In a recent review of the results in patients with melanoma treated on such regimens in combination with high-dose IL-2, an approximately 20-50% response rate has been observed. The factors associated with response are still unclear. Although we initially felt that it was associated with specific lysis, subsequent studies from our group suggest that the relevant factor is specific cytokine (INF-gamma, GM-CSF, TNF) production upon tumor stimulation. Additional studies will need to be done to clarify these issues.
引用
收藏
页码:33 / 47
页数:15
相关论文
共 74 条
[1]   LYSIS OF AUTOLOGOUS MELANOMA-CELLS BY TUMOR-INFILTRATING LYMPHOCYTES - ASSOCIATION WITH CLINICAL-RESPONSE [J].
AEBERSOLD, P ;
HYATT, C ;
JOHNSON, S ;
HINES, K ;
KORCAK, L ;
SANDERS, M ;
LOTZE, M ;
TOPALIAN, S ;
YANG, J ;
ROSENBERG, SA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (13) :932-937
[2]  
ASHER AL, 1991, J IMMUNOL, V146, P3227
[3]   ESTABLISHMENT OF CELL-TO-CELL CONTACT BY ADOPTIVELY TRANSFERRED ADHERENT LYMPHOKINE-ACTIVATED KILLER-CELLS WITH METASTATIC MURINE MELANOMA-CELLS [J].
BASSE, PH ;
NANNMARK, U ;
JOHANSSON, BR ;
HERBERMAN, RB ;
GOLDFARB, RH .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (13) :944-950
[4]   CLEARANCE RATES AND SYSTEMIC EFFECTS OF INTRAVENOUSLY ADMINISTERED INTERLEUKIN-2 (IL-2) CONTAINING PREPARATIONS IN HUMAN-SUBJECTS [J].
BINDON, C ;
CZERNIECKI, M ;
RUELL, P ;
EDWARDS, A ;
MCCARTHY, WH ;
HARRIS, R ;
HERSEY, P .
BRITISH JOURNAL OF CANCER, 1983, 47 (01) :123-133
[5]   TUMOR SUPPRESSION AFTER TUMOR-CELL TARGETED TUMOR-NECROSIS-FACTOR-ALPHA GENE-TRANSFER [J].
BLANKENSTEIN, T ;
QIN, ZH ;
UBERLA, K ;
MULLER, W ;
ROSEN, H ;
VOLK, HD ;
DIAMANTSTEIN, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (05) :1047-1052
[6]  
BRUBAKER JO, 1991, J IMMUNOL, V147, P1439
[7]   LOCAL-ADMINISTRATION OF CELLS CONTAINING AN INSERTED IL-2 GENE AND PRODUCING IL-2 INHIBITS GROWTH OF HUMAN-TUMORS IN NU NU MICE [J].
BUBENIK, J ;
VOITENOK, NN ;
KIELER, J ;
PRASSOLOV, VS ;
CHUMAKOV, PM ;
BUBENIKOVA, D ;
SIMOVA, J ;
JANDLOVA, T .
IMMUNOLOGY LETTERS, 1988, 19 (04) :279-282
[8]   CANCER-IMMUNOTHERAPY USING LOCAL INTERLEUKIN-2 ADMINISTRATION [J].
BUBENIK, J ;
INDROVA, M .
IMMUNOLOGY LETTERS, 1987, 16 (3-4) :305-309
[9]   IMMUNOTHERAPY OF CANCER USING LOCAL-ADMINISTRATION OF LYMPHOID-CELLS TRANSFORMED BY IL-2 CDNA AND CONSTITUTIVELY PRODUCING IL-2 [J].
BUBENIK, J ;
SIMOVA, J ;
JANDLOVA, T .
IMMUNOLOGY LETTERS, 1990, 23 (04) :287-292
[10]  
CAVALLO F, IN PRESS J IMMUNOL